Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
TER
0.35% p.a.
Distribution policy
Accumulating
Replication
Physical
Fund size
GBP 290 m
Inception Date
19 October 2017
Holdings
264
Overview
Description
The iShares Nasdaq US Biotechnology UCITS ETF seeks to track the Nasdaq Biotechnology index. The Nasdaq Biotechnology index tracks Nasdaq listed companies primarily engaged in biomedical research to develop new treatments and cures for human disease.
Documents
Chart
Basics
Data
| Index | Nasdaq Biotechnology |
| Investment focus | Equity, United States, Health Care |
| Fund size | GBP 290 m |
| Total expense ratio | 0.35% p.a. |
| Replication | Physical (Optimized sampling) |
| Legal structure | ETF |
| Strategy risk | Long-only |
| Sustainability | No |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in GBP) | 20.64% |
| Inception/ Listing Date | 19 October 2017 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | iShares |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Fund Services (Ireland) Limited |
| Investment Advisor | |
| Custodian Bank | State Street Custodial Services (Ireland) Limited, Dublin 2 |
| Revision Company | Deloitte |
| Fiscal Year End | 31 December |
| Swiss representative | BlackRock Asset Management Schweiz AG |
| Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
| Securities lending | Yes |
| Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
Similar ETFs
This section provides you with information on other ETFs with a similar investment focus to the iShares Nasdaq US Biotechnology UCITS ETF.
Similar ETFs via ETF search
Similar ETFs via investment guides
How do you like our ETF profile? Here you'll find our Questionnaire.
Holdings
Below you find information about the composition of the iShares Nasdaq US Biotechnology UCITS ETF.
Top 10 Holdings
Weight of top 10 holdings
out of 264
49.12%
| Gilead Sciences, Inc. | 10.12% |
| Amgen, Inc. | 9.04% |
| Vertex Pharmaceuticals | 8.48% |
| Regeneron Pharmaceuticals, Inc. | 7.34% |
| AstraZeneca PLC ADR | 4.26% |
| Alnylam Pharmaceuticals | 2.96% |
| Biogen, Inc. | 1.97% |
| argenx | 1.95% |
| Sanofi | 1.57% |
| Royalty Pharma | 1.43% |
Countries
| United States | 78.70% |
| Ireland | 1.45% |
| Germany | 1.10% |
| Other | 18.75% |
Sectors
| Health Care | 83.95% |
| Other | 16.05% |
As of 27/02/2025
Performance
Returns overview
| YTD | -13.63% |
| 1 month | -13.28% |
| 3 months | -15.98% |
| 6 months | -19.59% |
| 1 year | -8.49% |
| 3 years | -7.91% |
| 5 years | -3.79% |
| Since inception (MAX) | +13.72% |
| 2024 | +0.60% |
| 2023 | -1.59% |
| 2022 | +0.40% |
| 2021 | +0.80% |
Monthly returns in a heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 20.64% |
| Volatility 3 years | 22.91% |
| Volatility 5 years | 23.78% |
| Return per risk 1 year | -0.41 |
| Return per risk 3 years | -0.12 |
| Return per risk 5 years | -0.03 |
| Maximum drawdown 1 year | -23.05% |
| Maximum drawdown 3 years | -23.05% |
| Maximum drawdown 5 years | -30.57% |
| Maximum drawdown since inception | -30.57% |
Rolling 1 year volatility
Stock exchange
Listings
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | 2B70 | - - | - - | - |
| Stuttgart Stock Exchange | EUR | 2B70 | - - | - - | - |
| Bolsa Mexicana de Valores | MXN | - | BTEC1N MM | BTEC1N.MX | |
| London Stock Exchange | USD | BTEC | BTEC LN INAVBTEU | BTEC.L 0WXSINAV.DE | |
| London Stock Exchange | GBP | BTEK | BTEK LN INAVBTEU | BTEK.L 0WXSINAV.DE | |
| SIX Swiss Exchange | USD | BTEC | BTEC SE INAVBTEU | BTEC.S 0WXSINAV.DE | |
| XETRA | EUR | 2B70 | 2B70 GY INAVBTEE | BTEC.DE 0WXNINAV.DE |
Further information
Further ETFs on the Nasdaq Biotechnology index
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| Invesco Nasdaq Biotech UCITS ETF | 214 | 0.40% p.a. | Accumulating | Swap-based |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 21 | 0.35% p.a. | Distributing | Sampling |
Frequently asked questions
What is the name of BTEK?
The name of BTEK is iShares Nasdaq US Biotechnology UCITS ETF.
What is the ticker of iShares Nasdaq US Biotechnology UCITS ETF?
The primary ticker of iShares Nasdaq US Biotechnology UCITS ETF is BTEK.
What is the ISIN of iShares Nasdaq US Biotechnology UCITS ETF?
The ISIN of iShares Nasdaq US Biotechnology UCITS ETF is IE00BYXG2H39.
What are the costs of iShares Nasdaq US Biotechnology UCITS ETF?
The total expense ratio (TER) of iShares Nasdaq US Biotechnology UCITS ETF amounts to 0.35% p.a.. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately. Please have a look at our article for more information about the cost of ETFs.
Is iShares Nasdaq US Biotechnology UCITS ETF paying dividends?
iShares Nasdaq US Biotechnology UCITS ETF is an accumulating ETF. This means that dividends are not distributed to investors. Instead, dividends are reinvested in the fund on the ex-date, which leads to an increase of the ETF's share price.
What's the fund size of iShares Nasdaq US Biotechnology UCITS ETF?
The fund size of iShares Nasdaq US Biotechnology UCITS ETF is 290m GBP. See the following article for more information about the size of ETFs.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.